Pharmaceuticals

Global Non-Alcoholic Steatohepatitis Treatment Market Valuation and Growth Prospects: $13.57 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Non-Alcoholic Steatohepatitis Treatment Market Size?

The non-alcoholic steatohepatitis treatment market size has expanded significantly in recent years. It is projected to increase from $2.6 billion in 2024 to $3.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 37.5%. The historical growth in this sector is attributable to factors including the rising prevalence of NASH, enhanced awareness and diagnosis, pervasive lifestyle changes and the obesity epidemic, continued clinical research, improvements in healthcare infrastructure and access, alongside strong regulatory support and ongoing clinical trials.

The non-alcoholic steatohepatitis treatment market is projected to experience substantial expansion in the coming years. This market is forecast to reach $13.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 39.6%. Key drivers for this growth during the projection period include progress in drug development, greater awareness of the disease, an increase in its prevalence and associated risk factors, and a move towards personalized medicine approaches. Noteworthy trends expected during the forecast period encompass a patient-focused approach, ongoing technological innovations, the development of targeted therapies, an evolving regulatory environment, and breakthroughs in research.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Core Market Drivers Are Expanding The Non-Alcoholic Steatohepatitis Treatment Industry?

A growing incidence of insulin resistance is propelling the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when muscle, fat, and liver cells do not adequately respond to insulin, preventing easy absorption of glucose from the blood and resulting in high blood sugar. This condition is linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The prevalence of insulin resistance has risen significantly due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, in January 2022, a report from the International Diabetes Federation, a Belgium-based global diabetes community, stated that diabetes impacts 537 million individuals (20-79 years old), representing one in ten, and this figure is anticipated to climb to 643 million by 2030 and 783 million by 2045. Furthermore, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, projected new cases of liver cancer to reach 41,630 in 2024, up from 41,210 in 2023. Thus, the increased prevalence of insulin resistance, driven by various liver and diabetes diseases, will fuel the non-alcoholic steatohepatitis treatment market.

What Segment Insights Are Highlighted In The Non-Alcoholic Steatohepatitis Treatment Market Report?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Notable Trends Are Transforming The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

The progress in developing non-alcoholic steatohepatitis (NASH) drugs represents a key trend growing in prominence within the non-alcoholic steatohepatitis treatment market. Many corporations are allocating resources to formulate innovative medications for liver conditions that possess reduced adverse effects. For example, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology enterprise, secured a fast-track designation from the U.S. Food and Drug Administration (FDA). This designation aims to accelerate the creation of their non-alcoholic steatohepatitis (NASH) drugs, namely ervogastat and clesacostat. Fast Track is a procedure designed to support Pfizer’s investigative combination therapy for addressing non-alcoholic steatohepatitis (NASH) with liver fibrosis, referred to as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which Firms Are Driving Innovation Within The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Regional Trends Are Shaping Growth In The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2025, By The Business Research Company

Nutritional Analysis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Protein Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795